Non-small Cell Lung Cancer

  • Apichat TantraworasinEmail author
  • Sarawut Kongkarnka
  • Nirush Lertprasertsuke
  • Yutthaphan Wannasopha
  • Juntima Euathrongchit
  • Thatthan Suksombooncharoen
  • Somcharoen Saeteng
  • Sophon Siwachat
  • Busayamas Chewaskulyong


Non-small cell lung cancer (NSCLC) is most common cause of cancer death in the world. Early detection, diagnosis and treatments are the essential strategies for increased overall survival of patients. Recently, staging of NSCLC is updated to 8th edition of TNM staging for NSCLC issued by the IASLC which affects to overall survival and treatment methods. This chapter include the incidence and risk factors of lung cancer, screening for lung cancer, diagnostic investigation, pathology, stage, and current treatment modalities in each stage of disease. There are many issues in term of multimodality treatments including surgery, radiotherapy, chemotherapy, targeted therapy and immunotherapy.


NSCLC Diagnosis Stage Pathology Treatment modalities 



American Association for Thoracic Surgery


American College of Chest Physicians


American Cancer Society


Anaplastic Lymphoma Kinase


American Society of Clinical Oncology


Best Supportive Care


Concurrent Chemoradiotherapy


Confidence Interval


Centers for Medicare & Medicaid Services


Chronic Obstructive Pulmonary Disease


Disease-Free Survival


Endobronchial Ultrasound Needle Aspiration


Epidermal Growth Factor Receptor


European Society for Medical Oncology


Forced Expiratory Volume in 1 second


International Association Study of Lung Cancer




Large Cell Carcinoma


Lymph Node


Length of Hospital Stay


Lobe-Specific Node Dissection


Left Upper Lobe


Mediastinal Lymph Node


Median Survival


National Comprehensive Cancer Network


Non-small Cell Lung Cancer


Overall Survival


Progression-Free Survival


Quality of Life


Randomized Controlled Trial


Right Middle Lobe


Response Rate




Right Upper Lobe


Stereotactic Ablative Radiotherapy


Stereotactic Body Radiotherapy


Small Cell Carcinoma


Sequential Chemoradiotherapy


Systematic Lymph Node Dissection


Systematic Lymph Node Sampling


Squamous Cell Carcinoma


Transbronchial Needle Aspiration


Tyrosine Kinase Inhibitor


Transthoracic Needle Aspiration


US Preventive Services Task Force


Video-assisted Thoracoscopic Surgery


  1. 1.
    Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67(1):7–30CrossRefPubMedGoogle Scholar
  2. 2.
    Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C et al (2017) European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol 28(5):1117–1123CrossRefPubMedGoogle Scholar
  3. 3.
    Australian Institute of H, Welfare (2013) Cancer in Australia: actual incidence data from 1991 to 2009 and mortality data from 1991 to 2010 with projections to 2012. Asia Pac J Clin Oncol 9(3):199–213CrossRefGoogle Scholar
  4. 4.
    Sankaranarayanan R, Ramadas K, Qiao YL (2014) Managing the changing burden of cancer in Asia. BMC Med 12:3CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66(2):115–132CrossRefGoogle Scholar
  6. 6.
    Steinmaus C, Ferreccio C, Acevedo J, Yuan Y, Liaw J, Duran V et al (2014) Increased lung and bladder cancer incidence in adults after in utero and early-life arsenic exposure. Cancer Epidemiol Biomark Prev 23(8):1529–1538CrossRefGoogle Scholar
  7. 7.
    Beveridge R, Pintos J, Parent ME, Asselin J, Siemiatycki J (2010) Lung cancer risk associated with occupational exposure to nickel, chromium VI, and cadmium in two population-based case-control studies in Montreal. Am J Ind Med 53(5):476–485PubMedGoogle Scholar
  8. 8.
    Matrat M, Guida F, Mattei F, Cenee S, Cyr D, Fevotte J et al (2016) Welding, a risk factor of lung cancer: the ICARE study. Occup Environ Med 73(4):254–261CrossRefPubMedGoogle Scholar
  9. 9.
    Peters S, Kromhout H, Olsson AC, Wichmann HE, Bruske I, Consonni D et al (2012) Occupational exposure to organic dust increases lung cancer risk in the general population. Thorax 67(2):111–116CrossRefPubMedGoogle Scholar
  10. 10.
    Sha A (2016) 37P Domestic cooking fuel as a risk factor for lung cancer in women: a case control study. J Thorac Oncol 11(4 Suppl):S70–S71CrossRefGoogle Scholar
  11. 11.
    Olsson AC, Vermeulen R, Schuz J, Kromhout H, Pesch B, Peters S et al (2017) Exposure-response analyses of asbestos and lung cancer subtypes in a pooled analysis of case-control studies. Epidemiology 28(2):288–299CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Kim CH, Lee YC, Hung RJ, McNallan SR, Cote ML, Lim WY et al (2014) Exposure to secondhand tobacco smoke and lung cancer by histological type: a pooled analysis of the International Lung Cancer Consortium (ILCCO). Int J Cancer 135(8):1918–1930CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Masjedi MR, Naghan PA, Taslimi S, Yousefifard M, Ebrahimi SM, Khosravi A et al (2013) Opium could be considered an independent risk factor for lung cancer: a case-control study. Respiration 85(2):112–118CrossRefPubMedGoogle Scholar
  14. 14.
    Takiguchi Y, Sekine I, Iwasawa S, Kurimoto R, Tatsumi K (2014) Chronic obstructive pulmonary disease as a risk factor for lung cancer. World J Clin Oncol 5(4):660–666CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Liu Y, Zhu M, Geng J, Ban C, Zhang S, Chen W et al (2017) Incidence and radiologic-pathological features of lung cancer in Idiopathic pulmonary fibrosis. Clin Respir J 12(4):1700–1705CrossRefPubMedGoogle Scholar
  16. 16.
    Gawelek E, Drozdzowska B, Fuchs A (2017) Radon as a risk factor of lung cancer. Przegl Epidemiol 71(1):90–98PubMedGoogle Scholar
  17. 17.
    Torres-Duran M, Ruano-Ravina A, Parente-Lamelas I, Leiro-Fernandez V, Abal-Arca J, Montero-Martinez C et al (2014) Lung cancer in never-smokers: a case-control study in a radon-prone area (Galicia, Spain). Eur Respir J 44(4):994–1001CrossRefPubMedGoogle Scholar
  18. 18.
    Lin H, Huang YS, Yan HH, Yang XN, Zhong WZ, Ye HW et al (2015) A family history of cancer and lung cancer risk in never-smokers: a clinic-based case-control study. Lung Cancer 89(2):94–98CrossRefPubMedGoogle Scholar
  19. 19.
    Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown ST et al (2012) HIV as an independent risk factor for incident lung cancer. AIDS 26(8):1017–1025CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kaluzna EM, Rembowska J, Ziolkowska-Suchanek I, Swiatek-Koscielna B, Gabryel P, Dyszkiewicz W et al (2015) Heterozygous p.I171V mutation of the NBN gene as a risk factor for lung cancer development. Oncol Lett 10(5):3300–3304CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Fan J, Zhang W, Lei C, Qiao B, Liu Q, Chen Q et al (2015) Vascular endothelial growth factor polymorphisms and lung cancer risk. Int J Clin Exp Med 8(4):6406–6411PubMedPubMedCentralGoogle Scholar
  22. 22.
    Ezzeldin N, El-Lebedy D, Darwish A, El-Bastawissy A, Shalaby AE (2015) Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer. Contemp Oncol (Pozn) 19(6):441–445Google Scholar
  23. 23.
    Yamamoto Y, Kiyohara C, Suetsugu-Ogata S, Hamada N, Nakanishi Y (2017) Biological interaction of cigarette smoking on the association between genetic polymorphisms involved in inflammation and the risk of lung cancer: a case-control study in Japan. Oncol Lett 13(5):3873–3881CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Osawa Y, Osawa KK, Miyaishi A, Higuchi M, Tsutou A, Matsumura S et al (2007) NAT2 and CYP1A2 polymorphisms and lung cancer risk in relation to smoking status. Asian Pac J Cancer Prev 8(1):103–108PubMedGoogle Scholar
  25. 25.
    Fan H, Yu H, Deng H, Chen X (2014) Transforming growth factor-beta1 rs1800470 polymorphism is associated with lung cancer risk: a meta-analysis. Med Sci Monit 20:2358–2362CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Wang X, Ma K, Chi L, Cui J, Jin L, Hu JF et al (2016) Combining telomerase reverse transcriptase genetic variant rs2736100 with epidemiologic factors in the prediction of lung cancer susceptibility. J Cancer 7(7):846–853CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Qiao Q, Hu W (2013) The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects. Lung 191(4):369–377CrossRefPubMedGoogle Scholar
  28. 28.
    Cancer Genome Atlas Research N (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543–550CrossRefGoogle Scholar
  29. 29.
    Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB et al (2015) The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol 10(9):1243–1260CrossRefPubMedGoogle Scholar
  30. 30.
    Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II et al (2005) Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97(5):339–346CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Inamura K, Ninomiya H, Ishikawa Y, Matsubara O (2010) Is the epidermal growth factor receptor status in lung cancers reflected in clinicopathologic features? Arch Pathol Lab Med 134(1):66–72PubMedPubMedCentralGoogle Scholar
  32. 32.
    Ninomiya H, Hiramatsu M, Inamura K, Nomura K, Okui M, Miyoshi T et al (2009) Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer 63(2):235–240CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S et al (2012) RET, ROS1 and ALK fusions in lung cancer. Nat Med 18(3):378–381CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Kohno T, Ichikawa H, Totoki Y, Yasuda K, Hiramoto M, Nammo T et al (2012) KIF5B-RET fusions in lung adenocarcinoma. Nat Med 18(3):375–377CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Tantraworasin A, Lertprasertsuke N, Kongkarnka S, Euathrongchit J, Wannasopha Y, Saeteng S (2014) Retrospective study of ALK rearrangement and clinicopathological implications in completely resected non-small cell lung cancer patients in Northern Thailand: role of screening with D5F3 antibodies. Asian Pac J Cancer Prev 15(7):3057–3063CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Inamura K (2017) Lung Cancer: understanding its molecular pathology and the 2015 WHO Classification. Front Oncol 7:193CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Yatabe Y, Mitsudomi T, Takahashi T (2002) TTF-1 expression in pulmonary adenocarcinomas. Am J Surg Pathol 26(6):767–773CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD et al (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 365(5):395–409CrossRefGoogle Scholar
  39. 39.
    Ost DE, Yeung SC, Tanoue LT, Gould MK (2013) Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e121S–e141SCrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Tantraworasin A, Saeteng S, Lertprasertsuke N, Arreyakajohn N, Kasemsarn C, Patumanond J (2013) Prognostic factors of tumor recurrence in completely resected non-small cell lung cancer. Cancer Manag Res 5:77–84CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Fernandez-Ruiz M, Aranda-Arcas JL, Alonso-Navas F, Guerra-Vales JM (2007) Cardiac tamponade as initial clinical manifestation of a non-small cell lung cancer. Rev Clin Esp 207(11):587–589CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Marcos PJ, Rodriguez-Lorenzo A (2013) Sternal mass presenting as a first manifestation of lung cancer. Am J Med Sci 346(5):420CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Singh N, Kulkarni P, Aggarwal AN, Rai Mittal B, Gupta N, Behera D et al (2012) Choroidal metastasis as a presenting manifestation of lung cancer: a report of 3 cases and systematic review of the literature. Medicine (Baltimore) 91(4):179–194CrossRefGoogle Scholar
  44. 44.
    Sancho del Val L, Diez Redondo P, Ruiz-Zorrilla Lopez R, Lorenzo Pelayo S, Herranz Bachiller MT, Alcaide Suarez N et al (2012) Upper gastrointestinal bleeding as the first manifestation of lung cancer. Gastroenterol Hepatol 35(10):726–727CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Rakusic N, Baricevic D, Samarzija M, Jakopovic M, Baricevic M (2012) Acquired rhinophyma as a paraneoplastic manifestation of non-small cell lung cancer. Wien Klin Wochenschr 124(7–8):276–277CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Mohammad K, Sadikot RT (2009) Adrenal insufficiency as a presenting manifestation of nonsmall cell lung cancer. South Med J 102(6):665–667CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Oda S, Awai K, Funama Y, Utsunomiya D, Yanaga Y, Kawanaka K et al (2010) Detection of small pulmonary nodules on chest radiographs: efficacy of dual-energy subtraction technique using flat-panel detector chest radiography. Clin Radiol 65(8):609–615CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Pretreatment evaluation of non-small-cell lung cancer (1997) The American Thoracic Society and The European Respiratory Society. Am J Respir Crit Care Med 156(1):320–332CrossRefGoogle Scholar
  49. 49.
    Mayo JR, Aldrich J, Muller NL (2003) Radiation exposure at chest CT: a statement of the Fleischner Society. Radiology 228(1):15–21CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Hendee WR, O’Connor MK (2012) Radiation risks of medical imaging: separating fact from fantasy. Radiology 264(2):312–321CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Benko A, Fraser-Hill M, Magner P, Capusten B, Barrett B, Myers A et al (2007) Canadian Association of Radiologists: consensus guidelines for the prevention of contrast-induced nephropathy. Can Assoc Radiol J = Journal l’Association canadienne des radiologistes 58(2):79–87PubMedGoogle Scholar
  52. 52.
    Ohno Y, Koyama H, Lee HY, Yoshikawa T, Sugimura K (2016) Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET)/MRI for lung cancer staging. J Thorac Imaging 31(4):215–227CrossRefGoogle Scholar
  53. 53.
    Kluetz PG, Meltzer CC, Villemagne VL, Kinahan PE, Chander S, Martinelli MA et al (2000) Combined PET/CT imaging in oncology. Impact on patient management. Clin Positron Imaging 3(6):223–230CrossRefGoogle Scholar
  54. 54.
    Kligerman S, Digumarthy S (2009) Staging of non-small cell lung cancer using integrated PET/CT. AJR 193(5):1203–1211CrossRefGoogle Scholar
  55. 55.
    Kapoor V, McCook BM, Torok FS (2004) An introduction to PET-CT imaging. Radiographics 24(2):523–543CrossRefGoogle Scholar
  56. 56.
    Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA (2004) The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 78(3):1017–1023. discussion -23CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Antoch G, Stattaus J, Nemat AT, Marnitz S, Beyer T, Kuehl H et al (2003) Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 229(2):526–533CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Vansteenkiste JF, Stroobants SS (2006) PET scan in lung cancer: current recommendations and innovation. J Thorac Oncol 1(1):71–73CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE et al (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11(1):39–51CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Van Schil PE, Sihoe AD, Travis WD (2013) Pathologic classification of adenocarcinoma of lung. J Surg Oncol 108(5):320–326CrossRefPubMedGoogle Scholar
  61. 61.
    Travis WD, Brambilla E, Muller-Hermelink HK (2004) World Health Organization classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. IARC Press, LyonGoogle Scholar
  62. 62.
    Chen R, Ding Z, Zhu L, Lu S, Yu Y (2017) Correlation of clinicopathologic features and lung squamous cell carcinoma subtypes according to the 2015 WHO classification. Eur J Surg Oncol 43(12):2308–2314CrossRefPubMedGoogle Scholar
  63. 63.
    Kadota K, Nitadori J, Woo KM, Sima CS, Finley DJ, Rusch VW et al (2014) Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter, and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 9(8):1126–1139CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Howington JA, Blum MG, Chang AC, Balekian AA, Murthy SC (2013) Treatment of stage I and II non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e278S–e313SCrossRefPubMedGoogle Scholar
  65. 65.
    Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI et al (2011) Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the patient with N0 or N1 (less than hilar) non-small cell carcinoma: results of the American College of Surgery Oncology Group Z0030 Trial. J Thorac Cardiovasc Surg 141(3):662–670CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Liang W, He J, Shen Y, Shen J, He Q, Zhang J et al (2017) Impact of examined lymph node count on precise staging and long-term survival of resected non-small-cell lung cancer: a population study of the US SEER database and a Chinese multi-institutional registry. J Clin Oncol 35(11):1162–1170CrossRefPubMedGoogle Scholar
  67. 67.
    Tantraworasin A, Saeteng S, Siwachat S, Jiarawasupornchai T, Lertprasertsuke N, Kongkarnka S et al (2017) Impact of lymph node management on resectable non-small cell lung cancer patients. J Thorac Dis 9(3):666–674CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Hishida T, Saji H, Watanabe SI, Asamura H, Aokage K, Mizutani T et al (2017) A randomized phase III trial of lobe-specific vs. systematic nodal dissection for clinical stage I-II non-small cell lung cancer (JCOG1413). Jpn J Clin Oncol 48:1–5Google Scholar
  69. 69.
    Vannucci F, Gonzalez-Rivas D (2016) Is VATS lobectomy standard of care for operable non-small cell lung cancer? Lung Cancer 100:114–119CrossRefPubMedGoogle Scholar
  70. 70.
    Veronesi G (2013) Robotic surgery for the treatment of early-stage lung cancer. Curr Opin Oncol 25(2):107–114CrossRefPubMedGoogle Scholar
  71. 71.
    Heo W, Kang DK, Min HK, Jun HJ, Hwang YH (2017) Feasibility and safety of single-port video-assisted thoracic surgery for primary lung cancer. Korean J Thorac Cardiovasc Surg 50(3):190–196CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Mazzone P (2012) Preoperative evaluation of the lung resection candidate. Cleve Clin J Med 79(Electronic Suppl 1):eS17–eS22PubMedGoogle Scholar
  73. 73.
    Dziedzic R, Zurek W, Marjanski T, Rudzinski P, Orlowski TM, Sawicka W et al (2017) Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry. Eur J Cardiothorac Surg 52(2):363–369CrossRefPubMedGoogle Scholar
  74. 74.
    Albain KS, Swann RS, Rusch VW, Turrisi AT 3rd, Shepherd FA, Smith C et al (2009) Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet 374(9687):379–386CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    Guo SX, Jian Y, Chen YL, Cai Y, Zhang QY, Tou FF (2016) Neoadjuvant chemoradiotherapy vesus chemotherapy alone followed by surgery for resectable stage III non-small-cell lung cancer: a meta-analysis. Sci Rep 6:34388CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Kim AW, Boffa DJ, Wang Z, Detterbeck FC (2012) An analysis, systematic review, and meta-analysis of the perioperative mortality after neoadjuvant therapy and pneumonectomy for non-small cell lung cancer. J Thorac Cardiovasc Surg 143(1):55–63CrossRefPubMedGoogle Scholar
  77. 77.
    Donington JS, Pass HI (2014) Surgical resection of non-small cell lung cancer with N2 disease. Thorac Surg Clin 24(4):449–456CrossRefPubMedGoogle Scholar
  78. 78.
    Evans NR 3rd, Li S, Wright CD, Allen MS, Gaissert HA (2010) The impact of induction therapy on morbidity and operative mortality after resection of primary lung cancer. J Thorac Cardiovasc Surg 139(4):991–9916 e2CrossRefPubMedGoogle Scholar
  79. 79.
    Kamel MK, Nasar A, Stiles BM, Altorki NK, Port JL (2017) Video-assisted thoracoscopic lobectomy is the preferred approach following induction chemotherapy. J Laparoendosc Adv Surg Tech A 27(5):495–500CrossRefPubMedGoogle Scholar
  80. 80.
    Yang CF, Meyerhoff RR, Mayne NR, Singhapricha T, Toomey CB, Speicher PJ et al (2016) Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. Eur J Cardiothorac Surg 49(6):1615–1623CrossRefPubMedGoogle Scholar
  81. 81.
    Mehran R (2013) The role of surgery in patients with clinical n2 disease. Thorac Surg Clin 23(3):327–335CrossRefPubMedGoogle Scholar
  82. 82.
    Obiols C, Call S, Rami-Porta R, Trujillo-Reyes JC, Saumench R, Iglesias M et al (2013) Survival of patients with unsuspected pN2 non-small cell lung cancer after an accurate preoperative mediastinal staging. Ann Thorac Surg 97(3):957–964CrossRefPubMedGoogle Scholar
  83. 83.
    Ramnath N, Dilling TJ, Harris LJ, Kim AW, Michaud GC, Balekian AA et al (2013) Treatment of stage III non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e314S–e340SCrossRefPubMedGoogle Scholar
  84. 84.
    d’Amato TA, Ashrafi AS, Schuchert MJ, Alshehab DS, Seely AJ, Shamji FM et al (2009) Risk of pneumonectomy after induction therapy for locally advanced non-small cell lung cancer. Ann Thorac Surg 88(4):1079–1085CrossRefPubMedGoogle Scholar
  85. 85.
    Qin H, Wang C, Jiang Y, Zhang X, Zhang Y, Ruan Z (2015) Patients with single brain metastasis from non-small cell lung cancer equally benefit from stereotactic radiosurgery and surgery: a systematic review. Med Sci Monit 21:144–152CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Yuksel C, Bozkurt M, Yenigun BM, Enon S, Ozkan M, Kose SK et al (2013) The outcome of bifocal surgical resection in non-small cell lung cancer with synchronous brain metastases: results of a single center retrospective study. Thorac Cardiovasc Surg 62(7):605–611CrossRefPubMedGoogle Scholar
  87. 87.
    Yang SY, Kim DG, Lee SH, Chung HT, Paek SH, Hyun Kim J et al (2008) Pulmonary resection in patients with nonsmall-cell lung cancer treated with gamma-knife radiosurgery for synchronous brain metastases. Cancer 112(8):1780–1786CrossRefPubMedGoogle Scholar
  88. 88.
    Kong DS, Lee JI, Nam DH, Park K, Kim JH, Kim JG et al (2006) Prognosis of non-small cell lung cancer with synchronous brain metastases treated with gamma knife radiosurgery. J Korean Med Sci 21(3):527–532CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Choi JW, Kong DS, Seol HJ, Nam DH, Yoo KH, Sun JM et al (2016) Outcomes of gamma knife radiosurgery in combination with crizotinib for patients with brain metastasis from non-small cell lung cancer. World Neurosurg 95:399–405CrossRefPubMedGoogle Scholar
  90. 90.
    Yu XJ, Dai WR, Xu Y (2017) Survival outcome after stereotactic body radiation therapy and surgery for early stage non-small cell lung cancer: a meta-analysis. J Investig Surg 31:1–8Google Scholar
  91. 91.
    Schneider BJ, Daly ME, Kennedy EB, Stiles BM (2017) Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline summary. J Oncol Pract.
  92. 92.
    Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ et al (2008) Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 26(21):3552–3559CrossRefPubMedGoogle Scholar
  93. 93.
    Herskovic A, Mauer E, Christos P, Nagar H (2017) Role of postoperative radiotherapy in pathologic stage IIIA (N2) non-small cell lung cancer in a prospective Nationwide oncology outcomes database. J Thorac Oncol 12(2):302–313CrossRefPubMedGoogle Scholar
  94. 94.
    Curran WJ Jr, Paulus R, Langer CJ, Komaki R, Lee JS, Hauser S et al (2011) Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. J Natl Cancer Inst 103(19):1452–1460CrossRefPubMedPubMedCentralGoogle Scholar
  95. 95.
    Bradley JD, Paulus R, Komaki R, Masters G, Blumenschein G, Schild S et al (2015) Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study. Lancet Oncol 16(2):187–199CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R et al (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377(20):1919–1929CrossRefPubMedGoogle Scholar
  97. 97.
    Zhang XN, Huang L (2017) Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials. Oncotarget 8(52):90327–90337PubMedPubMedCentralGoogle Scholar
  98. 98.
    Felip E, Rosell R, Maestre JA, Rodriguez-Paniagua JM, Moran T, Astudillo J et al (2010) Preoperative chemotherapy plus surgery versus surgery plus adjuvant chemotherapy versus surgery alone in early-stage non-small-cell lung cancer. J Clin Oncol 28(19):3138–3145CrossRefPubMedGoogle Scholar
  99. 99.
    NSCLC Meta-Analyses Collaborative Group (2008) Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 26(28):4617–4625CrossRefPubMedCentralGoogle Scholar
  100. 100.
    Schrump DS, Carter D, Kelsey CR (2011) Non-small cell lung cancer in cancer. In: Principles & practice of oncology, 9th edn. Lippincott Williams & Wilkins, PhiladelphiaGoogle Scholar
  101. 101.
    Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92–98CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Ferry D, Billingham L, Jarrett H, Dunlop D, Woll PJ, Nicolson M et al (2017) Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: results from a British Thoracic Oncology Group randomised phase III trial. Eur J Cancer 83:302–312CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Saad AS, Ghali RR, Shawki MA (2017) A prospective randomized controlled study of cisplatin versus carboplatin-based regimen in advanced squamous nonsmall cell lung cancer. J Cancer Res Ther 13(2):198–203CrossRefPubMedGoogle Scholar
  104. 104.
    Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26(21):3543–3551CrossRefPubMedGoogle Scholar
  105. 105.
    Park CK, Oh IJ, Kim KS, Choi YD, Jang TW, Kim YS et al (2017) Randomized phase III study of docetaxel plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of nonsquamous non-small-cell lung cancer: a TRAIL Trial. Clin Lung Cancer 18(4):e289–ee96CrossRefPubMedGoogle Scholar
  106. 106.
    Zukin M, Barrios CH, Pereira JR, Ribeiro Rde A, Beato CA, do Nascimento YN et al (2013) Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2. J Clin Oncol 31(23):2849–2853CrossRefPubMedGoogle Scholar
  107. 107.
    Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N et al (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947–957CrossRefPubMedGoogle Scholar
  108. 108.
    Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13(3):239–246CrossRefPubMedGoogle Scholar
  109. 109.
    Yang JJ, Zhou Q, Yan HH, Zhang XC, Chen HJ, Tu HY et al (2017) A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. Br J Cancer 116(5):568–574CrossRefPubMedPubMedCentralGoogle Scholar
  110. 110.
    Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31(27):3327–3334CrossRefPubMedGoogle Scholar
  111. 111.
    Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH et al (2017) Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 378:113–125CrossRefPubMedGoogle Scholar
  112. 112.
    Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS et al (2017) Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med 376(7):629–640CrossRefPubMedGoogle Scholar
  113. 113.
    Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ (2012) Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 17(11):1351–1375CrossRefPubMedPubMedCentralGoogle Scholar
  114. 114.
    Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693–1703CrossRefPubMedPubMedCentralGoogle Scholar
  115. 115.
    Khozin S, Blumenthal GM, Zhang L, Tang S, Brower M, Fox E et al (2015) FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. Clin Cancer Res 21(11):2436–2439CrossRefPubMedGoogle Scholar
  116. 116.
    Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G et al (2016) FDA approval: alectinib for the treatment of metastatic, ALK-positive non-small cell lung cancer following Crizotinib. Clin Cancer Res 22(21):5171–5176CrossRefPubMedGoogle Scholar
  117. 117.
    Zhang S, Anjum R, Squillace R, Nadworny S, Zhou T, Keats J et al (2016) The potent ALK inhibitor Brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res 22(22):5527–5538CrossRefPubMedGoogle Scholar
  118. 118.
    Soria JC, Tan DSW, Chiari R, Wu YL, Paz-Ares L, Wolf J et al (2017) First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet 389(10072):917–929CrossRefPubMedGoogle Scholar
  119. 119.
    Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW et al (2017) Alectinib versus Crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377(9):829–838CrossRefPubMedGoogle Scholar
  120. 120.
    Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW et al (2017) Brigatinib in patients with Crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II Trial. J Clin Oncol 35(22):2490–2498CrossRefPubMedGoogle Scholar
  121. 121.
    Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A et al (2016) Resensitization to Crizotinib by the Lorlatinib ALK resistance mutation L1198F. N Engl J Med 374(1):54–61CrossRefPubMedGoogle Scholar
  122. 122.
    Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R et al (2009) Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 373(9674):1525–1531CrossRefPubMedGoogle Scholar
  123. 123.
    Lynch TJ, Patel T, Dreisbach L, McCleod M, Heim WJ, Hermann RC et al (2010) Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. J Clin Oncol 28(6):911–917CrossRefPubMedGoogle Scholar
  124. 124.
    Thatcher N, Hirsch FR, Luft AV, Szczesna A, Ciuleanu TE, Dediu M et al (2015) Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. Lancet Oncol 16(7):763–774CrossRefPubMedGoogle Scholar
  125. 125.
    Soria JC, Mauguen A, Reck M, Sandler AB, Saijo N, Johnson DH et al (2013) Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24(1):20–30CrossRefPubMedGoogle Scholar
  126. 126.
    de Boer RH, Arrieta O, Yang CH, Gottfried M, Chan V, Raats J et al (2011) Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 29(8):1067–1074CrossRefPubMedGoogle Scholar
  127. 127.
    Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E et al (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374(9699):1432–1440CrossRefPubMedGoogle Scholar
  128. 128.
    Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczesna A, Juhasz E et al (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol 11(6):521–529CrossRefPubMedGoogle Scholar
  129. 129.
    Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A et al (2006) Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542–2550CrossRefPubMedGoogle Scholar
  130. 130.
    Paz-Ares LG, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31(23):2895–2902CrossRefPubMedGoogle Scholar
  131. 131.
    Fidias PM, Dakhil SR, Lyss AP, Loesch DM, Waterhouse DM, Bromund JL et al (2009) Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. J Clin Oncol 27(4):591–598CrossRefPubMedPubMedCentralGoogle Scholar
  132. 132.
    Perol M, Chouaid C, Perol D, Barlesi F, Gervais R, Westeel V et al (2012) Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 30(28):3516–3524CrossRefPubMedPubMedCentralGoogle Scholar
  133. 133.
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH et al (2013) Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31(24):3004–3011CrossRefPubMedPubMedCentralGoogle Scholar
  134. 134.
    Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 18(12):2354–2362CrossRefPubMedPubMedCentralGoogle Scholar
  135. 135.
    Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18(10):2095–2103CrossRefGoogle Scholar
  136. 136.
    Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22(9):1589–1597CrossRefGoogle Scholar
  137. 137.
    Di Maio M, Chiodini P, Georgoulias V, Hatzidaki D, Takeda K, Wachters FM et al (2009) Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 27(11):1836–1843CrossRefGoogle Scholar
  138. 138.
    Reck M, Paz-Ares L, Bidoli P, Cappuzzo F, Dakhil S, Moro-Sibilot D et al (2017) Outcomes in patients with aggressive or refractory disease from REVEL: a randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer. Lung Cancer 112:181–187CrossRefGoogle Scholar
  139. 139.
    Reck M, Kaiser R, Mellemgaard A, Douillard JY, Orlov S, Krzakowski M et al (2014) Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol 15(2):143–155CrossRefPubMedPubMedCentralGoogle Scholar
  140. 140.
    Garon EB, Ciuleanu TE, Arrieta O, Prabhash K, Syrigos KN, Goksel T et al (2014) Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 384(9944):665–673CrossRefPubMedPubMedCentralGoogle Scholar
  141. 141.
    Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353(2):123–132CrossRefPubMedPubMedCentralGoogle Scholar
  142. 142.
    Kim ES, Hirsh V, Mok T, Socinski MA, Gervais R, Wu YL et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372(9652):1809–1818CrossRefPubMedGoogle Scholar
  143. 143.
    Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, Catala Ferrer M, Bravo I, Mendoza del Pino M et al (2008) Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer. J Clin Oncol 26(9):1452–1458CrossRefPubMedGoogle Scholar
  144. 144.
    Stanford JL, Stanford CA, O’Brien ME, Grange JM (2008) Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 44(2):224–227CrossRefPubMedGoogle Scholar
  145. 145.
    Nemunaitis J, Sterman D, Jablons D, Smith JW 2nd, Fox B, Maples P et al (2004) Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst 96(4):326–331CrossRefPubMedGoogle Scholar
  146. 146.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J et al (2006) Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 24(29):4721–4730CrossRefGoogle Scholar
  147. 147.
    Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D et al (2005) Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 23(27):6674–6681CrossRefPubMedGoogle Scholar
  148. 148.
    Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W et al (2013) Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol 31(19):2396–2403CrossRefPubMedGoogle Scholar
  149. 149.
    Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A et al (2011) Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol 12(12):1125–1133CrossRefGoogle Scholar
  150. 150.
    Govindan R, Szczesna A, Ahn MJ, Schneider CP, Gonzalez Mella PF, Barlesi F et al (2017) Phase III trial of Ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-small-cell lung cancer. J Clin Oncol 35(30):3449–3457CrossRefPubMedPubMedCentralGoogle Scholar
  151. 151.
    Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR et al (2017) Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol 18(1):31–41CrossRefPubMedPubMedCentralGoogle Scholar
  152. 152.
    Langendijk JA, ten Velde GP, Aaronson NK, de Jong JM, Muller MJ, Wouters EF (2000) Quality of life after palliative radiotherapy in non-small cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys 47(1):149–155CrossRefPubMedPubMedCentralGoogle Scholar
  153. 153.
    Ung YC, Yu E, Falkson C, Haynes AE, Stys-Norman D, Evans WK (2006) The role of high-dose-rate brachytherapy in the palliation of symptoms in patients with non-small-cell lung cancer: a systematic review. Brachytherapy 5(3):189–202CrossRefPubMedPubMedCentralGoogle Scholar
  154. 154.
    Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT et al (2013) Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 143(5 Suppl):e211S–ee50SCrossRefPubMedPubMedCentralGoogle Scholar
  155. 155.
    Zielinski M, Szlubowski A, Kolodziej M, Orzechowski S, Laczynska E, Pankowski J et al (2013) Comparison of endobronchial ultrasound and/or endoesophageal ultrasound with transcervical extended mediastinal lymphadenectomy for staging and restaging of non-small-cell lung cancer. J Thorac Oncol 8(5):630–636CrossRefPubMedPubMedCentralGoogle Scholar
  156. 156.
    Labarca G, Aravena C, Ortega F, Arenas A, Majid A, Folch E et al (2016) Minimally invasive methods for staging in lung cancer: systematic review and meta-analysis. Pulm Med 2016:1024709CrossRefPubMedPubMedCentralGoogle Scholar
  157. 157.
    Park SY, Kim BH, Kim JH, Lee S, Kang GH (2007) Panels of immunohistochemical markers help determine primary sites of metastatic adenocarcinoma. Arch Pathol Lab Med 131(10):1561–1567PubMedPubMedCentralGoogle Scholar
  158. 158.
    Cetinkaya E, Usluer O, Yilmaz A, Tutar N, Cam E, Ozgul MA et al (2017) Is endobronchial ultrasound-guided transbronchial needle aspiration an effective diagnostic procedure in restaging of non-small cell lung cancer patients? Endosc Ultrasound 6(3):162–167CrossRefPubMedPubMedCentralGoogle Scholar
  159. 159.
    Nasir BS, Bryant AS, Minnich DJ, Wei B, Dransfield MT, Cerfolio RJ (2014) The efficacy of restaging endobronchial ultrasound in patients with non-small cell lung cancer after preoperative therapy. Ann Thorac Surg 98(3):1008–1012CrossRefPubMedPubMedCentralGoogle Scholar
  160. 160.
    Genestreti G, Burgio MA, Matteucci F, Piciucchi S, Scarpi E, Monti M et al (2015) Endobronchial/endoesophageal ultrasound (EBUS/EUS) guided fine needle aspiration (FNA) and 18F-FDG PET/CT scanning in restaging of locally advanced non-small cell lung cancer (NSCLC) treated with chemo-radiotherapy: a mono-institutional pilot experience. Technol Cancer Res Treat 14(6):721–727CrossRefPubMedPubMedCentralGoogle Scholar
  161. 161.
    von Bartheld MB, Versteegh MI, Braun J, Willems LN, Rabe KF, Annema JT (2011) Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer. J Thorac Oncol 6(9):1510–1515CrossRefGoogle Scholar
  162. 162.
    De Waele M, Hendriks J, Lauwers P, Hertoghs M, Carp L, Salgado R et al (2011) Restaging the mediastinum in non-small cell lung cancer after induction therapy: non-invasive versus invasive procedures. Acta Chir Belg 111(3):161–164CrossRefPubMedPubMedCentralGoogle Scholar
  163. 163.
    de Cabanyes CS, Detterbeck FC (2010) A systematic review of restaging after induction therapy for stage IIIa lung cancer: prediction of pathologic stage. J Thorac Oncol 5(3):389–398CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Apichat Tantraworasin
    • 1
    Email author
  • Sarawut Kongkarnka
    • 2
  • Nirush Lertprasertsuke
    • 2
  • Yutthaphan Wannasopha
    • 3
  • Juntima Euathrongchit
    • 3
  • Thatthan Suksombooncharoen
    • 4
  • Somcharoen Saeteng
    • 1
  • Sophon Siwachat
    • 1
  • Busayamas Chewaskulyong
    • 4
  1. 1.Department of Surgery, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  2. 2.Department of Pathology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  3. 3.Department of Radiology, Faculty of MedicineChiang Mai UniversityChiang MaiThailand
  4. 4.Department of Internal Medicine, Faculty of MedicineChiang Mai UniversityChiang MaiThailand

Personalised recommendations